Iradimed (IRMD) Net Income towards Common Stockholders (2013 - 2026)

Iradimed (IRMD) has 14 years of Net Income towards Common Stockholders data on file, last reported at $5.8 million in Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders rose 24.13% year-over-year to $5.8 million in Q1 2026; TTM through Mar 2026 was $23.5 million, a 23.31% increase from a year earlier, with the FY2025 full-year figure at $22.4 million, up 20.87% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at $5.8 million, down from $6.4 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for IRMD reached as high as $6.4 million in Q4 2025 and fell as low as $2.5 million in Q1 2022.
• Historically, Net Income towards Common Stockholders has averaged $4.4 million across 5 years, with a median of $4.4 million in 2024.
• Across the five-year window, Net Income towards Common Stockholders jumped 120.53% in 2022 and retreated 16.59% in 2023, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at $3.7 million in 2022, then slipped by 16.59% to $3.1 million in 2023, then soared by 42.69% to $4.4 million in 2024, then jumped by 43.12% to $6.4 million in 2025, then slipped by 8.62% to $5.8 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were $5.8 million in Q1 2026, $6.4 million in Q4 2025, and $5.6 million in Q3 2025.